Metformin

GPTKB entity

Statements (82)

Predicate	Object
gptkbp:instance_of	gptkb:pharmaceuticals
gptkbp:approved_for_use	gptkb:FDA
gptkbp:approves	gptkb:1957 gptkb:FDA Adults
gptkbp:atccode	A10 BA02
gptkbp:available_on	generic drug
gptkbp:brand	gptkb:Metformin_HCl gptkb:Glucophage_XR gptkb:Riomet gptkb:Fortamet gptkb:Glucophage gptkb:Metformin_ER
gptkbp:can_be_combined_with	gptkb:Dapagliflozin gptkb:Dulaglutide
gptkbp:category	B
gptkbp:chemical_formula	C4 H11 N5
gptkbp:class	antidiabetic agent Biguanide
gptkbp:clinical_trial	Phase IV Phase III
gptkbp:clinical_use	combination therapy monotherapy first-line therapy
gptkbp:contraindication	Severe renal impairment renal impairment severe renal impairment acute or chronic metabolic acidosis
gptkbp:developed_by	gptkb:Bristol-Myers_Squibb
gptkbp:dosage_form	gptkb:tablet gptkb:liquid 500 mg 1000 mg 850 mg
gptkbp:effective_date	gptkb:1994
gptkbp:excretion	Urine
gptkbp:healthcare	gptkb:1994
https://www.w3.org/2000/01/rdf-schema#label	Metformin
gptkbp:indication	polycystic ovary syndrome glycemic control
gptkbp:interacts_with	gptkb:beer Alcohol iodinated contrast media
gptkbp:is_a_guide_for	gptkb:ADA NICE EASD
gptkbp:lifespan	6.2 hours
gptkbp:long_term_use_effect	vitamin B12 deficiency hypoglycemia risk low
gptkbp:marketed_as	gptkb:Australia gptkb:Boehringer_Ingelheim gptkb:Bristol-Myers_Squibb gptkb:Canada gptkb:India gptkb:UK gptkb:United_States various manufacturers
gptkbp:mechanism_of_action	biguanide increases insulin sensitivity Decreases hepatic glucose production decreases hepatic glucose production Biguanide
gptkbp:pharmacokinetics	excreted unchanged in urine not metabolized by liver
gptkbp:research_focus	weight loss cancer prevention anti-aging
gptkbp:route_of_administration	Oral oral
gptkbp:side_effect	nausea abdominal pain diarrhea lactic acidosis gastrointestinal upset Gastrointestinal upset Lactic acidosis
gptkbp:suitable_for	gestational diabetes PCOS
gptkbp:used_for	Type 2 diabetes type 2 diabetes
gptkbp:bfsParent	gptkb:Vitaminwater
gptkbp:bfsLayer	4